Skip Nav Destination
Issues
15 May 2022
-
Cover Image
Cover Image
The cover image shows GeoMx digital spatial profiler (DSP) imaging of a human head and neck squamous cell carcinoma section from a patient treated with αPD-1 immunotherapy. Immunofluorescence staining shows the presence of PanCK+ tumor cells (green), CD8+ T cells (red), and αSMA+ fibroblasts (yellow) with nuclei stained in blue. In this study, the authors identified a novel cancer-associated fibroblast subset predictive of αPD-1 immunotherapy response and associated with reduced T-cell exhaustion. For details, see the article by Obradovic and colleagues on page 2094 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Review
Clinical Trials: Targeted Therapy
Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Valentina Boni; Mary J. Fidler; Hendrik-Tobias Arkenau; Alexander Spira; Funda Meric-Bernstam; Nataliya Uboha; Rachel E. Sanborn; Randy F. Sweis; Patricia LoRusso; Misako Nagasaka; Javier Garcia-Corbacho; Shadia Jalal; James J. Harding; Stella K. Kim; Iris H.C. Miedema; Danielle J. Vugts; Marc C. Huisman; Gerben J.C. Zwezerijnen; Guus A.M.S. van Dongen; C. Willemien Menke van der Houven van Oordt; Song Wang; Tam Dang; Ivan A. Zein; Olga Vasiljeva; Susan K. Lyman; Virginia Paton; Alison Hannah; Joyce F. Liu
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab
Todd L. Rosenblat; Michael R. McDevitt; Jorge A. Carrasquillo; Neeta Pandit-Taskar; Mark G. Frattini; Peter G. Maslak; Jae H. Park; Dan Douer; Dragan Cicic; Steven M. Larson; David A. Scheinberg; Joseph G. Jurcic
Clinical Trials: Immunotherapy
Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity
Brian Orr; Haider Mahdi; Yusi Fang; Mary Strange; Ibrahim Uygun; Mainpal Rana; Lixin Zhang; Adria Suarez Mora; Alexandra Pusateri; Esther Elishaev; Chaeryon Kang; George Tseng; William Gooding; Robert P. Edwards; Pawel Kalinski; Anda M. Vlad
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Joaquim Bellmunt; Ronald de Wit; Yves Fradet; Miguel A. Climent; Daniel P. Petrylak; Jae-Lyun Lee; Lawrence Fong; Andrea Necchi; Cora N. Sternberg; Peter H. O'Donnell; Thomas Powles; Elizabeth R. Plimack; Dean F. Bajorin; Arjun V. Balar; Daniel Castellano; Toni K. Choueiri; Stephane Culine; Winald Gerritsen; Howard Gurney; David I. Quinn; Jacqueline Vuky; Nicholas J. Vogelzang; Razvan Cristescu; Jared Lunceford; Assieh Saadatpour; Andrey Loboda; Junshui Ma; Mohini Rajasagi; James Luke Godwin; Blanca Homet Moreno; Petros Grivas
Precision Medicine and Imaging
HPV and DNA Methylation Testing in Urine for Cervical Intraepithelial Neoplasia and Cervical Cancer Detection
Rianne van den Helder; Renske D.M. Steenbergen; Annina P. van Splunter; Constantijne H. Mom; Ming Y. Tjiong; Ivonne Martin; Fleur M.F. Rosier-van Dunné; Irene A.M. van der Avoort; Maaike C.G. Bleeker; Nienke E. van Trommel
Single‐Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment
Kavitha Yaddanapudi; Bryce F. Stamp; Priyanka B. Subrahmanyam; Andrei Smolenkov; Sabine J. Waigel; Rahul Gosain; Michael E. Egger; Robert C.G. Martin; Robert Buscaglia; Holden T. Maecker; Kelly M. McMasters; Jason A. Chesney
Translational Cancer Mechanisms and Therapy
Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Aleksandar Obradovic; Diana Graves; Michael Korrer; Yu Wang; Sohini Roy; Abdullah Naveed; Yaomin Xu; Adam Luginbuhl; Joseph Curry; Michael Gibson; Kamran Idrees; Paula Hurley; Peng Jiang; X. Shirley Liu; Ravindra Uppaluri; Charles G. Drake; Andrea Califano; Young J. Kim
Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
Keigo Chida; Akihito Kawazoe; Toshihiro Suzuki; Masahito Kawazu; Toshihide Ueno; Kazumasa Takenouchi; Yoshiaki Nakamura; Yasutoshi Kuboki; Daisuke Kotani; Takashi Kojima; Hideaki Bando; Saori Mishima; Takeshi Kuwata; Naoya Sakamoto; Jun Watanabe; Hiroyuki Mano; Masafumi Ikeda; Kohei Shitara; Itaru Endo; Tetsuya Nakatsura; Takayuki Yoshino
Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE
Michele L. LeNoue-Newton; Sheau-Chiann Chen; Thomas Stricker; David M. Hyman; Natalie Blauvelt; Philippe L. Bedard; Funda Meric-Bernstam; Rinaa S. Punglia; Deborah Schrag; Eva M. Lepisto; Fabrice Andre; Lillian Smyth; Semih Dogan; Celeste Yu; Chetna Wathoo; Mia Levy; Lisa D. Eli; Feng Xu; Grace Mann; Alshad S. Lalani; Fei Ye; Christine M. Micheel; Monica Arnedos; on behalf of AACR Project GENIE Consortium
Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy
Jiannong Li; Inna Smalley; Zhihua Chen; Jheng-Yu Wu; Manali S. Phadke; Jamie K. Teer; Thanh Nguyen; Florian A. Karreth; John M. Koomen; Amod A. Sarnaik; Jonathan S. Zager; Nikhil I. Khushalani; Ahmad A. Tarhini; Vernon K. Sondak; Paulo C. Rodriguez; Jane L. Messina; Y. Ann Chen; Keiran S.M. Smalley
Aberrant Activation of Cell-Cycle–Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma
Kosuke Yoshida; Akira Yokoi; Tomofumi Yamamoto; Yusuke Hayashi; Jun Nakayama; Tsuyoshi Yokoi; Hiroshi Yoshida; Tomoyasu Kato; Hiroaki Kajiyama; Yusuke Yamamoto
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma
Malin Hultcrantz; Even H. Rustad; Venkata Yellapantula; Allison Jacob; Theresia Akhlaghi; Neha Korde; Sham Mailankody; Alexander M. Lesokhin; Hani Hassoun; Eric L. Smith; Oscar B. Lahoud; Heather J. Landau; Gunjan L. Shah; Michael Scordo; David J. Chung; Sergio Giralt; Elli Papaemmanuil; Ola Landgren
Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer
Lucia Viganò; Alberta Locatelli; Adele Ulisse; Barbara Galbardi; Matteo Dugo; Diego Tosi; Carlo Tacchetti; Tiziana Daniele; Balázs Győrffy; Lorenzo Sica; Marina Macchini; Milvia Zambetti; Stefania Zambelli; Giampaolo Bianchini; Luca Gianni
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Shiyou Wei; Delong Yin; Shengnan Yu; Xiang Lin; Milan R. Savani; Kuang Du; Yin Ku; Di Wu; Shasha Li; Hao Liu; Meng Tian; Yaohui Chen; Michelle Bowie; Seethalakshmi Hariharan; Matthew Waitkus; Stephen T. Keir; Eric T. Sugarman; Rebecca A. Deek; Marilyne Labrie; Mustafa Khasraw; Yiling Lu; Gordon B. Mills; Meenhard Herlyn; Kongming Wu; Lunxu Liu; Zhi Wei; Keith T. Flaherty; Kalil Abdullah; Gao Zhang; David M. Ashley
Corrections
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
George D. Demetri; Filippo De Braud; Alexander Drilon; Salvatore Siena; Manish R. Patel; Byoung Chul Cho; Stephen V. Liu; Myung-Ju Ahn; Chao-Hua Chiu; Jessica J. Lin; Koichi Goto; Jeeyun Lee; Lyudmila Bazhenova; Thomas John; Marwan Fakih; Sant P. Chawla; Rafal Dziadziuszko; Takashi Seto; Sebastian Heinzmann; Bethany Pitcher; David Chen; Timothy R. Wilson; Christian Rolfo
Correction: Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell Immunity
Yichen Chen; Jun Wang; Xi Wang; Xinye Li; Jingjing Song; Juan Fang; Xiangqi Liu; Tao Liu; Dikan Wang; Qunxing Li; Shuqiong Wen; Da Ma; Juan Xia; Liqun Luo; Song Guo Zheng; Jun Cui; Gucheng Zeng; Lieping Chen; Bin Cheng; Zhi Wang
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.